Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12

Journal of Clinical Oncology

Volumn 32, Issue 31, 2014, Pages 3490-3496

  Crump, Michael ^a   Kuruvilla, John ^a   Couban, Stephen ^h   MacDonald, David A ^h   Kukreti, Vishal ^a   Kouroukis, C Tom ^c   Rubinger, Morel ⁱ   Buckstein, Rena ^b   Imrie, Kevin R ^b   Federico, Massimo ^m   Di Renzo, Nicola ⁿ   Howson Jan, Kang ^d   Baetz, Tara ^e   Kaizer, Leonard ^g   Voralia, Michael ^j   Olney, Harold J ^k   Turner, A Robert ^l   Sussman, Jonathan ^c   Hay, Annette E ^f   Djurfeldt, Marina S ^f   Meyer, Ralph M ^c,f   Chen, Bingshu E ^f   Shepherd, Lois E ^f   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e Dept of Obstetrics and Gynecology   (United States)

^f Clinical Trials Group   (Canada)

^g CREDIT VALLEY HOSPITAL   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ CANCERCARE MANITOBA   (Canada)

^j Saskatoon Cancer Center   (Canada)

^k NOTRE DAME HOSPITAL   (Canada)

^l CROSS CANCER INSTITUTE   (Canada)

^m UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁿ VITO FAZZI HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; GEMCITABINE; RITUXIMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; EMBOLISM; EVENT FREE SURVIVAL; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REFRACTORY AGGRESSIVE LYMPHOMA; RELAPSED AGGRESSIVE LYMPHOMA; THROMBOCYTE TRANSFUSION; THROMBOSIS; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; AUTOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DEOXYCYTIDINE; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; QUALITY OF LIFE; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84911498561     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.9593     Document Type: Article

References (25)

1. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
2. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010
3. Baetz T, Belch A, Couban S, et al: Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14:1762-1767, 2003
4. Crump M, Baetz T, Couban S, et al: Gemcitabine, dexamethasone and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101:1835-1842, 2004
5. Jaffe ES, Harris NL, Stein H, et al: WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
6. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
7. [No authors listed]: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
8. White SJ, Freedman LS: Allocation of patients to treatments groups in a controlled clinical study. Br J Cancer 37:849-857, 1978
9. Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas :NCI-Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
10. National Cancer Institute Cancer Therapy Evaluation Program: Common Toxicity Criteria Version 2.0 (NCI CTC v2.0). http://ctep. cancer.gov/protocolDevelopment/electronic-applications/docs/ctcv20-4-30-992.pdf
11. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
12. Eremenco S, Webster K, Kutikova L, et al Development and multilingual validation of the FACT-Lymphoma Instrument. Qual Life Res 13 1501, 2004 (abstr 1124)
13. 2 tests. Biometrics 10:417-451, 1954
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
16. Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related quality of life data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41:280-287, 2005
17. Girouard C, Dufresne J, Imrie K, et al: Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 8:675-680, 1997
18. Jerkeman M, Leppä S, Kvaløy S, et al: ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma: The Nordic Lymphoma Group experience. Eur J Haematol 73:179-182, 2004
19. Josting A, Sieniawski M, Glossmann JP, et al High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study. Ann Oncol 16:1359-1365, 2005
20. Guglielmi C, Gomez F, Philip T, et al: Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 16:3264-3269, 1998
21. + diffuse large B-cell lymphoma: Final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. J Clin Oncol 30:4462-4469, 2012
22. Blay J, Gomez F, Sebban C, et al: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial-Parma Group. Blood 92 3562-3568, 1998
23. Martín A, Conde E, Arnan M, et al: R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome-A GEL/TAMO study. Haematologica 93:1829-1836, 2008
24. Thieblemont C, Briere J, Mounier N, et al: The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study. J Clin Oncol 29 4079-4087, 2011
25. Yang Y, Shaffer AL 3rd, Emre NC, et al Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21:723-737, 2012